- |||||||||| dasatinib / Generic mfg.
Trial primary completion date, Metastases: Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) - Oct 13, 2016 P2, N=386, Active, not recruiting, N=30 --> 0 | Suspended --> Withdrawn | Trial primary completion date: Dec 2018 --> Mar 2017 Trial primary completion date: Jun 2015 --> Dec 2016
- |||||||||| RG4733 / Roche
Trial completion, Enrollment change, Trial primary completion date, Combination therapy: RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma (clinicaltrials.gov) - Sep 29, 2015 P1, N=22, Completed, Recruiting --> Completed | N=150 --> 180 | Trial primary completion date: Dec 2008 --> Jul 2009 Active, not recruiting --> Completed | N=34 --> 22 | Trial primary completion date: May 2017 --> Jun 2013
- |||||||||| Trial primary completion date: Yoga Therapy in Treating Patients With Malignant Brain Tumors (clinicaltrials.gov) - Aug 13, 2015
P=N/A, N=9, Terminated, Active, not recruiting --> Completed | N=34 --> 22 | Trial primary completion date: May 2017 --> Jun 2013 Trial primary completion date: Dec 2013 --> Sep 2012
- |||||||||| dasatinib / Generic mfg.
Enrollment change, Trial primary completion date, Metastases: Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) - Dec 19, 2014 P2, N=386, Active, not recruiting, Recruiting --> Suspended N=502 --> 386 | Trial primary completion date: Dec 2014 --> Jun 2015
- |||||||||| vatalanib (PTK787) / Novartis, Bayer
Trial completion, Trial primary completion date: Vatalanib in Treating Patients With Recurrent or Progressive Meningioma (clinicaltrials.gov) - Oct 27, 2014 P2, N=25, Completed, Active, not recruiting --> Completed | Trial primary completion date: Oct 2015 --> Oct 2014 Active, not recruiting --> Completed | Trial primary completion date: Apr 2014 --> Nov 2010
- |||||||||| dasatinib / Generic mfg.
Trial primary completion date, Metastases: Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) - Jun 19, 2014 P2, N=502, Active, not recruiting, Trial primary completion date: Oct 2014 --> Oct 2015 Trial primary completion date: Dec 2013 --> Dec 2014
- |||||||||| cixutumumab (IMC A12) / Eli Lilly
Enrollment closed, Metastases: Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 10, 2013 P1, N=50, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
|